Cholesterol, the weakness of anaplastic large cell lymphoma (ALCL)

Cholesterol, the weakness of anaplastic large cell lymphoma (ALCL)

Anaplastic large-cell lymphoma (ALCL) is a category of non-Hodgkin lymphoma involving aberrant T cells or null lymphocytes. It is aggressive and often relapse. Scientists continue developing new therapies to treat this cancer.

In recent Nature journal, Garcia-Bermudez et al. reported that cholesterol auxotrophy is a promising strategy for the treatment of ALCL. They found that ALK+ ALCL cell lines is auxotrophic for cholesterol due to genetic defect and thus highly expressing LDLR for cholesterol uptake. The authors further demonstrated that LDLR depletion inhibited the growth of mouse tumour xenografts derived from ALK+ ALCL cancer cell lines. Their data identify cholesterol uptake through LDLR as a therapeutic target for ALK+ ALCL.

arigo offer quality antibodies to facilitate the research of cholesterol metabolism and ALCL.

ALCL pathological markers

ALK antibody
CD3 antibody [SQab1713]
CD30 antibody [SQab1723]


Cholesterol uptake & metabolism

LDLR antibody (ARG56530)
PCSK9 antibody (ARG56535)
SOAT1 antibody (ARG56476)

SOAT2 antibody (ARG57814)

ACAT1 antibody (ARG54705)


More Lymphoma marker antibodies

Reference: Garcia-Bermudez et al., (2019) Nature. doi: 10.1038/s41586-019-0945-5.